Angina pectoris caused by rigidity of artery coronaria; chronic stable angina pectoris.
Dosage/Direction for Use
IV bolus Initially 0.25 mg/kg of actual body wt for >2 min (20 mg for patients w/ ave wt). If insufficient response, a 2nd dose can be given after 15 min. 0.35 mg/kg of actual body wt for >2 min (25 mg for patients w/ ave wt). IV infusion Given after administration of 20 mg (0.25 mg/kg) or 25 mg (0.35 mg/kg) Diltiasan direct IV inj & after a decrease in heart rate. Infusion rate can be increased from 5 to 15 mg/hr. Can be maintained up to 24 hr.
Contraindications
Hypersensitivity. Sick sinus syndrome, patient w/ AV block (level 2 of 3), severe hypotension or cardiogenic shock, atrium fibrillation or atrial flutter, ventricular tachycardia.
Special Precautions
CHF. May cause symptomatic hypotension. Additive effect in prolonging AV conduction when used concomitantly w/ β-blocker or digitalis glycoside. Impaired kidney or liver function. Pregnancy. Not recommended for use in nursing women. Childn.
Adverse Reactions
Hypersensitivity (rash, pruritus). Bradycardia, dizziness, headache, dry mouth, red face, swollen foot, GI disorder (pyrosis, less appetite, nausea, diarrhea, abdominal discomfort, constipation). Shoulder & joints pain.
C08DB01 - diltiazem ; Belongs to the class of benzothiazepine derivative selective calcium-channel blockers with direct cardiac effects. Used in the treatment of cardiovascular diseases.
Sign Out
